HemaSphere
(Jun 2022)
P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
- F. B. Askeland,
- E. Haukås,
- T. S. Slørdahl,
- D. Schjøll,
- A. Lysen,
- E. Hermansen,
- F. Schjesvold
Affiliations
- F. B. Askeland
- 1 Oslo Myeloma Center, Department of Hematology
- E. Haukås
- 3 Department of Cancer and Blood Diseases, Stavanger University Hospital, Stavanger
- T. S. Slørdahl
- 4 Department of Hematology, St. Olavs Hospital, Trondheim, Norway
- D. Schjøll
- 5 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo
- A. Lysen
- 1 Oslo Myeloma Center, Department of Hematology
- E. Hermansen
- 6 Department of Hematology, Zealand Iniversity Hospital, Roskilde, Denmark
- F. Schjesvold
- 1 Oslo Myeloma Center, Department of Hematology
- DOI
-
https://doi.org/10.1097/01.HS9.0000846428.64094.91
- Journal volume & issue
-
Vol. 6
pp.
780
– 781
WeChat QR code